mercredi 25 octobre 2017

Onco Actu du 25 octobre 2017

1. Biologie

Cancer biology still needs physicists [Nature]

2.6 Etiologie - Environnement

Glyphosate in the Age of Stupid [The Risk-Monger]

IARC rejects false claims in Reuters article (“In glyphosate review, WHO cancer agency edited out “non-carcinogenic” findings”) [IARC]

3.1.1 Prévention - Tabac - e-cigs

MPs launch inquiry into e-cigarettes over fears they could 're-normalise' smoking for teens [The Telegraph]

E-cigarettes: Cross-party group of MPs launches inquiry [BBC News]

Swapping Cigarettes for Vaping [The Scientist]

3.6 Prévention - Activité physique

Walking below minimum recommended levels linked to lower mortality risk [ACS]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance medical device innovation and help patients gain faster access to beneficial technologies [FDA]

4.7 Dép., diag. & prono. - Col de l'utérus

Previous screening results important for smear-test decision after age 60 [Karolinska Institutet]

5. Traitements

Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients [Penn Medicine]

Actually, Many New Cancer Drugs May Be Helpful And Worth Trying [Forbes]

Internal radiotherapy: tackling cancer from within [Cancer Research UK]

5.12 Immunothérapies

When Hope Runs Out, Cancer Patients Are Making Their Own DIY Immunotherapy Treatments [Gizmodo]

5.12.1 Immunothérapies - partenariats

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics [EndPoints]

5.12.7 Immunothérapies - vaccins

Viral Vector Mobilan Offers a New Approach for Cancer Immunotherapy [Roswell Park Cancer Institute]

5.2.3 Pharma - économie

What’s driving the rapid growth of the top 20 biopharma companies in the world? [EndPoints]

5.4 Traitements - Economie

Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst [FiercePharma]

6. Lutte contre les cancers

The Transformation Of Medical Education From Choosing More To Choosing Wisely [Health Affairs Blog]

6.4 Médico-éco

Robotic-assisted surgery: more expensive, but not always more effective [Reuters]

6.9 Controverses

French scientists in uproar over changes to medical-research clusters [Nature]